Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Cert. of designation
Quarterly results
Director departure
9 METERS BIOPHARMA, INC. (INNT) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/15/2023 8-K Quarterly results
Docs: "9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023"
11/15/2021 8-K Investor presentation, Quarterly results
Docs: "9 Meters Biopharma Provides Business Update and Reports Financial Results for the Third Quarter 2021",
"FOCUSED ON RARE AND UNMET NEEDS IN DIGESTIVE DISEASES AND UNIQUE GI BIOLOGY"
03/22/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "9 Meters Biopharma, Inc. Provides Business Update and Announces Third Quarter 2020 Results Phase 1b/2a trial with a proprietary long-acting GLP-1 agonist in short bowel syndrome top-line data expected in Q4 Continued enrollment of Phase 3 trial with larazotide in celiac disease, interim analysis remains on target for 1H 2021"
08/12/2020 8-K Quarterly results
08/08/2019 8-K Quarterly results
Docs: "Innovate Biopharmaceuticals Reports Second Quarter 2019 Results and Corporate Updates Company is exploring potential strategic opportunities and non-dilutive sources of capital and partnerships Continued activities of the first Phase 3 clinical trial for celiac disease including the screening and monitoring of potential subjects RALEIGH, N.C., Aug. 8, 2019 -- Innovate Biopharmaceuticals, Inc. , a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today reported its second quarter 2019 financial results and corporate updates. Recent Developments Clinical"
03/19/2019 8-K Quarterly results
Docs: "Innovate Biopharmaceuticals Reports Financing to Initiate the First Phase 3 Clinical Trial in Celiac Disease, Fiscal Year 2018 Earnings and Key Corporate Highlights Innovate closes an equity financing with gross proceeds of $9.7 million Continued launch activities for start of the first Phase 3 celiac disease trial, expected to start Q2 2019 Continued research collaborations studying new indications for larazotide: known mechanism of action involving benefits of reducing intestinal permeability RALEIGH, N.C., March 19, 2019, Innovate Biopharmaceuticals, Inc. , a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, announced today that on March 18, 2019, it closed its previously announced equity financing, resulting in gross..."
11/13/2018 8-K Quarterly results
Docs: "Innovate Biopharmaceuticals Reports Third Quarter 2018 Earnings and Key Corporate Highlights • Poster presentation at the American Association of Study of Liver Diseases showing promising pre-clinical data of larazotide acetate in NASH reducing intestinal permeability. Innovate plans to initiate a Phase 2 clinical trial for NASH in 2019 • Continued startup activities for launch of the first Phase 3 celiac disease trial which is targeted in the first half of 2019 • Continued research collaborations studying new indications for larazotide, which have known mechanism of action involving benefits of reducing permeability and large markets with unmet needs"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy